PAH Agents- Endothelin Receptor Antagonists

PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1)

PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1)

PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1) These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells

These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells

These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression

By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression

By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression